MindWalk (NASDAQ:HYFT) Stock Rating Upgraded by Zacks Research

MindWalk (NASDAQ:HYFT) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Monday,Zacks.com reports.

Separately, Weiss Ratings assumed coverage on shares of MindWalk in a report on Wednesday, January 14th. They issued a “sell (d-)” rating for the company. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Reduce”.

MindWalk Trading Down 0.7%

MindWalk stock opened at $1.38 on Monday. The company has a quick ratio of 4.09, a current ratio of 4.19 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $63.70 million, a P/E ratio of -2.30 and a beta of 0.51. MindWalk has a 52 week low of $0.27 and a 52 week high of $3.25.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of HYFT. Bank of Montreal Can increased its position in shares of MindWalk by 81.0% during the fourth quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock valued at $100,000 after buying an additional 24,500 shares during the period. Renaissance Technologies LLC boosted its position in shares of MindWalk by 8.4% during the fourth quarter. Renaissance Technologies LLC now owns 239,080 shares of the company’s stock valued at $435,000 after purchasing an additional 18,600 shares in the last quarter. Jane Street Group LLC grew its stake in MindWalk by 147.3% in the fourth quarter. Jane Street Group LLC now owns 161,202 shares of the company’s stock worth $293,000 after purchasing an additional 96,018 shares during the period. Finally, Bridgeway Capital Management LLC purchased a new stake in MindWalk in the fourth quarter worth about $91,000. 6.70% of the stock is owned by institutional investors.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.